Product News and Recalls

Article points out Yaz clot risks

A story in the Toledo Blade from Ohio mentions the increased risk of blood clots from Yaz and its sister drug, Yasmin.

The story points out that numerous studies indicate Yaz and Yasmin carry two-to-three times the risk of blood clots compared to other types of birth control pills on the market.

The U.S. Food and Drug Administration changed the labeling of the pills in April to reflect that added risk. The label change also applied to the pills Beyaz and Ocella, which – like Yaz and Yasmin – contain the artificial hormone drospirenone.

The article says the increased risk “shouldn’t be ignored,” because blood clots can cause potentially fatal heart attacks, strokes and blockages. In fact, numerous lawsuits have been filed by women who suffered from blood clots and related injuries.

The article also points out that Yaz and Yasmin were heavily marketed for a wide range of symptoms. They were among the top-selling birth control pills in the United States, with worldwide sales of about $1.8 billion in 2008. But recent concerns of serious health ramifications have hurt the line’s image.

Patients should consult their doctors before making any changes in their medication. A consultation with a Beyaz lawyer is also important if there are significant injuries.

See the story here: